TradingViewTradingView

Cardiff Oncology (CRDF) Gets FDA Fast Track for Onvansertib

Menos de 1 minuto de leitura

The FDA granted Fast Track designation to onvansertib with FOLFIRI/bevacizumab for first-line KRAS- or NRAS-mutated metastatic colorectal cancer. In the Phase 2 trial, the 30 mg regimen had a 72.2% confirmed response rate versus 42.1% with standard care alone.

Material Details

#DetailAI Analyst View
1FDA grants Fast Track for first-line RAS-mutated mCRCMay facilitate development and review, but does not change approval standards or guarantee approval.
2Confirmed response rate: 72.2% vs 42.1%The 30 mg regimen showed a 30-point improvement over FOLFIRI/bevacizumab alone in the intent-to-treat population.
3Median PFS not reached vs approx. 11 monthsAs of September 28, 2026, median PFS was not reached in the 30 mg arm; combined standard-of-care arms were approximately 11 months.

Context by AI Analyst

This is a clinical and regulatory milestone for a clinical-stage company advancing onvansertib toward a planned registrational trial. Initiation of that trial and subsequent efficacy and safety data would be needed to establish a larger catalyst.

Based on the original press release from Cardiff Oncology, Inc. distributed by GlobeNewswire.

Aviso legal